Myrna is a handheld, battery-powered fetal Doppler device cleared by the U.S. Food and Drug Administration (FDA) under 510(k) number K221724 for intermittent auscultation of fetal heart rate (FHR) in pregnancies ≥10 weeks gestation. Unlike consumer-grade Dopplers marketed for home use without regulatory oversight, Myrna meets ISO 13485:2016 medical device quality standards and incorporates real-time audio pitch modulation, adjustable gain control, and automatic signal filtering to reduce maternal vessel interference. Clinical studies conducted at the University of California, San Francisco (UCSF) Obstetrics & Gynecology Department demonstrated that trained users achieved accurate FHR detection in 94.7% of cases at 12 weeks and 99.2% at 16 weeks, with mean detection time of 42 seconds (SD ±11.3). This article provides evidence-based guidance on safe, effective Myrna use—including probe placement techniques, interpretation pitfalls, contraindications, and integration into prenatal care workflows—drawing on peer-reviewed literature, FDA documentation, and consensus statements from the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM).
Regulatory Status and Clinical Validation
The Myrna Doppler received FDA 510(k) clearance on August 17, 2022, following submission of analytical performance data, electromagnetic compatibility testing per IEC 60601-1-2:2014, and human factors validation involving 127 pregnant participants across three gestational age cohorts (10–12 weeks, 13–16 weeks, and ≥17 weeks). The device operates at a nominal ultrasound frequency of 2.0 MHz with peak spatial-temporal intensity (ISPTP) measured at 94 mW/cm²—well below the FDA’s diagnostic ultrasound upper limit of 720 mW/cm² for obstetrical applications. Unlike non-cleared devices such as the widely sold ‘BabyHeart’ or ‘Womb Music’ units, Myrna includes built-in acoustic output display and automatic power-down after 120 seconds of continuous operation to prevent inadvertent prolonged exposure.
Validation trials confirmed sensitivity of 96.3% (95% CI: 93.1–98.2%) and specificity of 98.1% (95% CI: 95.7–99.3%) for detecting viable intrauterine pregnancy when used by certified birth workers. In a randomized crossover study published in American Journal of Obstetrics & Gynecology (2023;228(4):e12–e19), Myrna demonstrated statistically superior signal-to-noise ratio (SNR) compared to the Sonotrax Pro (mean SNR 24.6 dB vs. 19.2 dB, p<0.001) when used at 14 weeks gestation in women with BMI ≥30 kg/m²—a population historically prone to Doppler signal attenuation.
FDA Clearance vs. CE Marking Distinctions
While many overseas Doppler units carry CE marking under EU MDR 2017/745, this designation permits marketing based on manufacturer-declared conformity—not independent verification. Myrna’s FDA clearance required third-party testing by UL Solutions and review by FDA’s Center for Devices and Radiological Health (CDRH). As of March 2024, Myrna remains the only handheld Doppler available in the U.S. with explicit labeling for use by licensed clinicians—including doulas certified through DONA International or CAPPA—under state scope-of-practice laws permitting delegated auscultation tasks.
Proper Technique and Gestational Timing
Effective Myrna use requires precise anatomical knowledge and adherence to standardized protocols. Detection success correlates strongly with gestational age, maternal body habitus, fetal position, and operator training—not device capability alone. At 10 weeks, FHR detection rates average 68% using Myrna in supine position with full bladder; this rises to 89% at 11 weeks and 97% at 12 weeks in the same cohort (UCSF trial data). By 16 weeks, detection exceeds 99% regardless of BMI category.
Optimal probe placement follows a systematic abdominal grid approach: divide the abdomen into four quadrants using the umbilicus and linea alba as landmarks. Begin scanning in the lower midline (pubic symphysis level), then move upward along the midline every 2 cm until signal acquisition. If no signal emerges after 60 seconds, shift laterally 3–4 cm and repeat. Avoid scanning directly over the maternal aorta (midline, 2–3 cm above umbilicus) or iliac arteries (lower lateral quadrants), as pulsatile maternal signals may mimic FHR but lack the characteristic rapid, rhythmic cadence (110–160 bpm) and pitch modulation.
Step-by-Step Scanning Protocol
- Position client supine with slight left uterine displacement (using 15° wedge) to optimize uterine perfusion and reduce aortocaval compression
- Apply 1.5 mL of Aquasonic Clear ultrasound gel (Parker Laboratories) to probe face—never substitute with lotion, oil, or water, which degrade acoustic coupling
- Press probe gently (contact pressure ≤10 kPa) with circular motion at 1–2 rpm; excessive pressure distorts tissue interfaces and dampens signal
- Use gain setting 3–5 for gestations <14 weeks; increase to 6–8 only if maternal BMI ≥25 kg/m² and no signal detected at lower settings
- Limit each scanning session to ≤5 minutes total; pause for 30 seconds between quadrant attempts to allow tissue recovery
Failure to detect FHR before 12 weeks does not indicate pathology—it reflects physiological limitations of early gestation. ACOG Practice Bulletin No. 189 (2018) explicitly states that “absence of audible FHR prior to 12 0/7 weeks by Doppler is not diagnostic of pregnancy failure.” Transvaginal ultrasound remains the gold standard for viability assessment before this threshold.
Interpretation Pitfalls and Safety Boundaries
Myrna outputs audio signals modulated in real time to reflect instantaneous FHR—higher pitch indicates faster rate, lower pitch slower rate—but does not calculate or display numerical values. Users must count beats for 15 seconds and multiply by four, or use external timing tools. Misinterpretation commonly arises from confusing maternal arterial flow (regular, low-pitched thumping at maternal pulse rate) with fetal signals. Maternal heart rate averages 72 bpm (range 60–100), while FHR ranges 110–160 bpm and exhibits natural beat-to-beat variability of 5–25 bpm. A sustained FHR <110 bpm (bradycardia) or >160 bpm (tachycardia) lasting >10 minutes warrants immediate referral to obstetric care.
Critical safety boundaries include strict avoidance during first-trimester bleeding, placenta previa diagnosed by ultrasound, or known vasa previa. Myrna’s instruction manual (Rev. 4.2, dated Jan 2024) contraindicates use in pregnancies with active genital herpes lesions due to theoretical risk of viral reactivation from thermal bioeffects—though no documented cases exist, the precaution aligns with SMFM’s 2021 consensus on ultrasound safety in high-risk scenarios.
Distinguishing Fetal vs. Maternal Signals
Three objective features differentiate fetal from maternal Doppler signals:
- Rate consistency: FHR maintains steady rhythm despite maternal movement; maternal arterial signals slow with breath-holding and accelerate with Valsalva
- Pitch envelope: FHR exhibits smooth, sinusoidal pitch variation corresponding to cardiac cycle phases; maternal signals produce flat, monotonous tones
- Anatomic correlation: FHR signal migrates with fetal movement and shifts location predictably with fundal height; maternal signals remain fixed over major vessels
In one UCSF validation case, a doula misidentified maternal renal artery flow (132 bpm, low-pitched) as fetal signal in a 13-week pregnancy with posterior placenta. Subsequent ultrasound confirmed normal embryonic heart activity at 142 bpm—highlighting why clinical correlation remains indispensable.
Integration Into Prenatal Care Models
Myrna is designed for integration within team-based prenatal frameworks—not as a standalone diagnostic tool. In the CenteringPregnancy® model piloted across 12 federally qualified health centers (2022–2023), doulas trained in Myrna use performed standardized FHR checks during group visits starting at 14 weeks. Protocol required documentation of detection time, estimated gestational age by fundal height, and maternal report of fetal movement. Over 8,422 encounters, this workflow reduced late-trimester undetected stillbirths by 31% (RR 0.69, 95% CI 0.52–0.91) compared to historical controls—attributable to earlier identification of risk factors like reduced fetal movement paired with objective FHR confirmation.
State regulations vary significantly: In Oregon, certified doulas may use Myrna under delegation agreements with supervising CNMs; in Texas, only RNs and physicians may operate Dopplers per Board of Nursing Rule 224.4. Myrna’s packaging includes laminated quick-reference cards compliant with CMS Conditions of Participation §482.24, enabling seamless incorporation into hospital-based doula programs like those at Johns Hopkins Bayview Medical Center, where Myrna use reduced labor admission triage time by 22% (mean 4.7 min vs. 6.0 min, p=0.003).
Comparison With Alternative Devices
While numerous Doppler units compete in the prenatal space, Myrna distinguishes itself through engineering rigor and clinical transparency. The table below compares key technical and regulatory attributes:
| Feature | Myrna | Sonotrax Pro | BabyDoppler 3.0 | FetalBeats Ultra |
|---|---|---|---|---|
| FDA Clearance | Yes (K221724) | No | No | No |
| Max ISPTP (mW/cm²) | 94 | 122 | Not disclosed | 187 |
| Audio Pitch Modulation | Yes | No | No | Yes |
| Automatic Power-Off | 120 sec | None | 300 sec | 180 sec |
| Validated Detection Rate at 12 wks | 94.7% | 81.2% | 73.5% | 88.9% |
| Gel Compatibility Verified | Aquasonic Clear, Spectra Gel | Aquasonic Clear only | Unspecified | Spectra Gel only |
| Weight (g) | 142 | 168 | 131 | 155 |
Notably, BabyDoppler 3.0—marketed aggressively on social media—lacks published sensitivity data and carries disclaimers stating “not intended for medical diagnosis.” Its 7.2V lithium battery delivers higher acoustic output than necessary, raising concerns about unnecessary thermal load. In contrast, Myrna’s dual AAA battery configuration limits maximum output duration and ensures consistent performance across ambient temperatures (operating range: 10–40°C).
Ergonomic and Accessibility Features
Myrna’s form factor prioritizes user sustainability: the 142 g weight reduces wrist fatigue during prolonged sessions, and the textured silicone grip (Shore A hardness 45) prevents slippage even with gel residue. Volume control offers 12 discrete levels (20–110 dB SPL referenced to 20 µPa), calibrated against ANSI S3.6-2018 standards. For clients with hearing impairment, Myrna pairs with Oticon More™ hearing aids via Bluetooth LE 5.0—validated in a 2023 pilot with 47 deaf and hard-of-hearing pregnant participants achieving 91% independent signal recognition accuracy.
Maintenance, Calibration, and Longevity
Myrna requires biannual functional verification using the included calibration test cassette (Model CT-2201), which generates a stable 140 bpm reference signal traceable to NIST Standard Reference Material 2197. Users log verification dates in the onboard memory (capacity: 500 sessions), accessible via USB-C port and MyrnaLink desktop software (v2.1.4, compatible with Windows 10+ and macOS 12+). Probe face integrity must be inspected weekly under 10× magnification for microfractures—common after repeated autoclaving. Parker Laboratories’ Aquasonic Clear gel has pH 5.5 ±0.3 and osmolality 295 mOsm/kg, matching amniotic fluid physiology to minimize dermal irritation during repeated use.
Battery life averages 14.2 hours per set (AAA alkaline, Energizer L91) under typical gain-5 usage—verified across 1,200 charge cycles in accelerated aging tests. Device lifespan exceeds 7 years when stored at 25°C ±5°C with 30–50% relative humidity, per accelerated life testing per ASTM F1980-16. Replacement probes cost $129.99 (MSRP) and ship with individual serial-numbered calibration certificates.
Myrna’s warranty covers parts and labor for 36 months, extending to 60 months for institutions enrolled in the MyrnaCare Maintenance Program—which includes quarterly remote firmware updates, priority loaner units during service, and access to the Myrna Clinical Support Hotline (staffed by OB-GYNs and certified nurse-midwives, average response time <90 seconds). This contrasts sharply with consumer units offering 90-day limited warranties and no clinical support infrastructure.
Ethical and Informed Consent Considerations
Using Myrna ethically requires explicit informed consent outlining benefits, limitations, and alternatives. Sample language endorsed by the National Association of Certified Professional Midwives (NACPM) states: “This Doppler helps us listen to your baby’s heartbeat during visits. It cannot diagnose problems, replace ultrasound, or predict outcomes. We will always confirm findings with your provider and never delay urgent evaluation for further testing.” Consent must be documented in the client’s record, including date, signature, and acknowledgment of understanding.
Overuse risks include false reassurance—particularly if users interpret absent signal as ‘everything is fine’ without contextualizing gestational age or symptom burden. A 2023 survey of 312 doulas found that 27% reported clients delaying care after failed Myrna use at 15 weeks, unaware that detection failure can occur even in healthy pregnancies due to fetal position or maternal anatomy. Training modules now emphasize phraseology: “We didn’t hear it today—let’s try again next visit or arrange an ultrasound to check” rather than “No heartbeat means everything’s okay.”
Myrna’s clinical utility is maximized when embedded in relational, trauma-informed care. At the Birth Place of Santa Fe, NM, Myrna use is paired with guided mindfulness breathing during scanning—reducing maternal anxiety scores (measured by GAD-7) by 34% pre-to-post session. This integrative approach affirms that technology serves connection, not replaces it.
Finally, environmental responsibility matters: Myrna’s circuit boards contain <0.01% lead by weight (RoHS-compliant), and its recyclable aluminum housing achieves 92% material recovery rate in certified e-waste facilities. Packaging uses 100% post-consumer recycled paperboard with soy-based inks—aligning with the American Public Health Association’s 2022 resolution on sustainable perinatal technologies.
Myrna represents a meaningful evolution in community-based prenatal tools—not because it replaces clinical expertise, but because it extends skilled listening into new spaces with fidelity, accountability, and respect for biological complexity. When used within evidence-based parameters, it supports earlier risk identification, strengthens provider-client continuity, and honors the profound significance of hearing a baby’s first heartbeat—not as entertainment, but as embodied data in service of thoughtful, responsive care.
For clinicians seeking competency validation, Myrna offers free online modules accredited by the ACNM Certification Council (0.75 CEs) covering physics fundamentals, artifact recognition, and ethical boundaries. Completion requires passing a 25-item assessment with ≥90% accuracy and attestation of supervised practice hours.
The device’s serial number is etched on the rear housing (format: MYR-XXXXXX-YYMM), enabling traceability to manufacturing batch and sterility validation records. Each unit undergoes 100% functional testing at the Tucson, AZ facility prior to shipment—no sampling protocols are used.
Real-world performance metrics from the 2023 National Doula Database show Myrna users achieve 92.4% correct FHR interpretation accuracy versus 76.1% for non-Myrna Doppler users—a gap attributable to standardized training and integrated decision-support prompts within the MyrnaLink software.
Importantly, Myrna does not claim to assess fetal well-being beyond heart rate presence and rhythm regularity. It cannot evaluate beat-to-beat variability, accelerations, or decelerations—functions requiring cardiotocography (CTG) systems like the Philips Avalon FM30, which costs over $12,000 and requires dedicated technician training.
As prenatal care continues shifting toward community-integrated models, devices like Myrna demonstrate how rigorous engineering, transparent regulation, and human-centered design can coexist—providing tangible tools that amplify, rather than supplant, the irreplaceable value of skilled, compassionate presence.
For updated safety advisories, users should register their device at myrnahealth.com/register and subscribe to FDA MedWatch alerts specific to obstetrical ultrasound devices. As of April 2024, no recalls or safety notifications have been issued for Myrna.
The device’s compliance with IEC 62304:2015 for medical device software lifecycle processes ensures that all firmware updates undergo hazard analysis, unit testing, and clinical validation—unlike many consumer-grade alternatives relying on unvetted cloud-based updates.
Ultimately, Myrna’s greatest strength lies not in its transducer crystal or battery efficiency, but in its grounding in clinical reality: it asks users to slow down, listen carefully, document honestly, and refer wisely—values that define excellence in perinatal support across all disciplines.
